The Dermatology Digest

JANUARY 21, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE), with limited systemic exposure, according to two studies presented at the 2024 Maui Dermatology conference. What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified. Enter JAK inhibition.

Safety 36

Safety Eczema Social Media Dermatology 36

The Dermatology Digest

FEBRUARY 14, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Therapy Dermatitis Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

DECEMBER 19, 2023

The primary endpoint of the clinical trial was safety and tolerability. Statistical significance was achieved for improvement in patient-reported eczema severity; the clinically relevant threshold of improvement by 4 or more points was met in six patients (75%). No patients experienced flare requiring rescue therapy.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

OCTOBER 26, 2024

Level Up is a phase 3b/4 global, randomized, open-label, efficacy assessor-blinded, head-to-head, multi-center study evaluating upadacitinib vs. dupilumab in adolescents and adults with moderate-to-severe AD who had an inadequate response to systemic therapy or when the use of those therapies was inadvisable. In the switchers, 47.6%

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

The Dermatology Digest

MARCH 11, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

OCTOBER 5, 2023

Barr, MD, dual board-certified integrative dermatologist, certified somatic trauma therapy practitioner, Somatic Skin Science, Seattle, Washington. “It The DNA Connection Deep in our DNA, there’s a primordial theme of slowing down, connection, and safety, said Dr. Barr. Oftentimes we feel like something is coming at us.

Safety 36

Safety Social Media Therapy Sun Protection 36

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. Recommend proactive therapy with topical corticosteroids or topical calcineurin inhibitors for patients with a relapsing course of AD. Urge consideration for once-daily dosing of topical medications.

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36

US Dermatologt Partners

JANUARY 24, 2024

Multiple sclerosis (MS) –People with MS, especially those who receive disease-modifying therapies, are significantly more likely to develop psoriasis, according to research presented at the 2021 Consortium of Multiple Sclerosis Centers. Symptoms include abdominal cramping, changes in bowel movements, and blood in the stool.

Management 36

Management Skin Health Medical Dermatology 36

Aesthetics Advisor

JUNE 18, 2024

Consider medical treatments: Fillers, laser therapy, and surgery may be required for severe or persistent dark circles. As someone with very sensitive skin, I've also had my fair share of breakouts when trying a new formula (especially when it comes to eye creams, as I'm very prone to eczema around my eyelids).

Vitamin C 36

Vitamin C Extractions Hydration Makeup 36

Alison Bladh

JANUARY 1, 2025

Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatologic Therapy.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

First Derm

DECEMBER 26, 2023

Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a. Eczema (Dermatitis): Symptoms : Red, itchy, scaly patches on the scalp. 7] Triggers and Aggravators Common for Eczema and Psoriasis : Stress, hormonal changes, and environmental factors.

Management 49

Management Dermatitis Eczema Consultation 49

The Dermatology Digest

AUGUST 4, 2023

According to Dr. Richard, today she uses many approaches, including biologics (as monotherapy and in combination), as well as phototherapy, to treat patients with psoriasis, eczema, vitiligo, and a “laundry list” of other skin diseases that respond to light. Phototherapy usage trends in the U.S. Many patients prefer non-systemic options.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 42.3% difference vs. placebo. In the lower dose group, 36.3% difference vs. placebo.

Dermatitis 36

Dermatitis Safety Office Eczema 36

The Dermatology Digest

JANUARY 8, 2024

This study was a 16-week, Phase 2, randomized, double-blind, parallel group, placebo controlled, dose-ranging, multicenter study that evaluated the safety and efficacy of lutikizumab in 153 adult patients with moderate to severe HS who had previously failed anti-TNF therapy. Serious adverse events (SAEs) occurred in 5.3%

Medical 36

Medical Clinic Therapy Eczema 36

Lydia Sarfati

MARCH 13, 2024

A recently published study from the Cleveland Clinic shows that integrative therapies that include massage therapy, can improve the physical, mental and social health for patients with chronic, non-cancer related pain without increased use of opioid medications.

Facial Massage 45

Facial Massage Facials Surgery Tools 45

US Dermatologt Partners

SEPTEMBER 23, 2024

Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes. A dermatologist can provide treatments like: Laser therapy – lasers may be used around the eye area for a multitude of purposes. These treatments can be very effective but are not without risk.

Treatments 41

Treatments Chemical Peels Skincare Routine Sun Protection 41

The Dermatology Digest

FEBRUARY 8, 2024

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

FEBRUARY 24, 2025

of children treated with roflumilast cream achieved a 75% improvement in the Eczema Area and Severity Index (EASI-75) at Week 4 compared to 20.6% Safety and tolerability results were consistent with previous trials of roflumilast cream 0.15% in patients aged 6 years with AD. Fully 35.3% for vehicle-treated subjects. of patients.

Eczema 67

Eczema Dermatitis Safety Dermatology 67

Lipgloss and Aftershave

APRIL 4, 2025

Her commitment deepened when her own children faced skin challengesher son with eczema and her daughter with cystic acnesolidifying her mission to create skin-loving solutions where the market had fallen short. This dual mechanismantimicrobial and anti-inflammatorymakes Magnolia officinalis a paradigm shift in acne therapy.

Vitamin C 75

Vitamin C Ingredients Collagen Skincare 75